This was 1 year ago
LocationBrussels
This two-day event in Brussels for security policymakers, practitioners and researchers is the inaugural symposium of the Horizon Europe-funded Engage2innovate security research project. Speakers and delegates will discuss empowering impactful security R&I outputs.
Realising Security Innovation will present and discuss the results of E2i research examining what constitutes real security innovation including:
Realising Security Innovation will open with a keynote address from Nicolas Bessot, Head of Innovation and Security Research Unit at the Directorate-General for Migration and Home Affairs of the European Commission.
The symposium will include presentations, discussions and — on day 2 — a DesignLab workshop. This interactive group session will explore the potential for human-centred social innovation as an enabler of security solutions, and collaboratively investigate and develop conceptual models that might describe this.
Realising Security Innovation will critically explore different approaches said to foster the implementation of R&I project outputs — including end-user and citizen engagement, Social Innovation, and Responsible Research & Innovation (RRI).
Registration for this event is now open here.
Please visit the event website for updated information.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.